Last reviewed · How we verify
Anti-tumor necrosis factor alpha agents
Anti-tumor necrosis factor alpha agents is a Anti-TNF agents Small molecule drug developed by El-Hussuna, Alaa, M.D.. It is currently in Phase 2 development for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis. Also known as: Biologics.
Anti-tumor necrosis factor alpha agents work by blocking the action of tumor necrosis factor-alpha (TNF-alpha), a protein involved in systemic inflammation.
Anti-tumor necrosis factor alpha agents work by blocking the action of tumor necrosis factor-alpha (TNF-alpha), a protein involved in systemic inflammation. Used for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis.
At a glance
| Generic name | Anti-tumor necrosis factor alpha agents |
|---|---|
| Also known as | Biologics |
| Sponsor | El-Hussuna, Alaa, M.D. |
| Drug class | Anti-TNF agents |
| Target | TNF-alpha |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
TNF-alpha is a cytokine that promotes inflammation and is involved in the pathogenesis of various autoimmune and inflammatory diseases. By blocking TNF-alpha, anti-TNF agents can reduce inflammation and slow disease progression.
Approved indications
- Rheumatoid arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Crohn's disease
- Ulcerative colitis
Common side effects
- Infections
- Allergic reactions
- Increased risk of lymphoma
- Neurological events
Key clinical trials
- Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (PHASE3)
- Association of Erectile Dysfunction With Neuropathic Pain, Disease Activity, and Functional Status in Male Patients With Axial Spondyloarthritis: A Cross-Sectional Observational Study
- Lumbar Spinal Fibrosis and TNF Alpha Inhibition (PHASE3)
- Stand UP to Rheumatoid Arthritis (SUPRA) (NA)
- Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis (PHASE4)
- Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis (PHASE3)
- A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects (PHASE1)
- A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-tumor necrosis factor alpha agents CI brief — competitive landscape report
- Anti-tumor necrosis factor alpha agents updates RSS · CI watch RSS
- El-Hussuna, Alaa, M.D. portfolio CI
Frequently asked questions about Anti-tumor necrosis factor alpha agents
What is Anti-tumor necrosis factor alpha agents?
How does Anti-tumor necrosis factor alpha agents work?
What is Anti-tumor necrosis factor alpha agents used for?
Who makes Anti-tumor necrosis factor alpha agents?
Is Anti-tumor necrosis factor alpha agents also known as anything else?
What drug class is Anti-tumor necrosis factor alpha agents in?
What development phase is Anti-tumor necrosis factor alpha agents in?
What are the side effects of Anti-tumor necrosis factor alpha agents?
What does Anti-tumor necrosis factor alpha agents target?
Related
- Drug class: All Anti-TNF agents drugs
- Target: All drugs targeting TNF-alpha
- Manufacturer: El-Hussuna, Alaa, M.D. — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Rheumatoid arthritis
- Indication: Drugs for Psoriatic arthritis
- Indication: Drugs for Ankylosing spondylitis
- Also known as: Biologics
- Compare: Anti-tumor necrosis factor alpha agents vs similar drugs
- Pricing: Anti-tumor necrosis factor alpha agents cost, discount & access